
Cytodyn Inc
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $0.1999
- Today's High:
- $0.22
- Open Price:
- $0.205
- 52W Low:
- $0.15
- 52W High:
- $1.26
- Prev. Close:
- $0.21
- Volume:
- 562828
Company Statistics
- Market Cap.:
- $250.94 million
- Book Value:
- -0.128
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-73277000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -133.19%
- Return on Equity TTM:
- 0%
Company Profile
Cytodyn Inc had its IPO on under the ticker symbol CYDY.
The company operates in the Healthcare sector and Biotechnology industry. Cytodyn Inc has a staff strength of 23 employees.
Stock update
Shares of Cytodyn Inc opened at $0.21 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.2 - $0.22, and closed at $0.2.
This is a -4.76% slip from the previous day's closing price.
A total volume of 562,828 shares were traded at the close of the day’s session.
In the last one week, shares of Cytodyn Inc have slipped by -9.09%.
Cytodyn Inc's Key Ratios
Cytodyn Inc has a market cap of $250.94 million, indicating a price to book ratio of 1066.0343 and a price to sales ratio of 1174.391.
In the last 12-months Cytodyn Inc’s revenue was $0 with a gross profit of $-73277000 and an EBITDA of $-115555000. The EBITDA ratio measures Cytodyn Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cytodyn Inc’s operating margin was 0% while its return on assets stood at -133.19% with a return of equity of 0%.
In Q0.66666666666667, Cytodyn Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Cytodyn Inc’s PE and PEG Ratio
- Forward PE
- 10.8108
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.2 per share while it has a forward price to earnings multiple of 10.8108 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cytodyn Inc’s profitability.
Cytodyn Inc stock is trading at a EV to sales ratio of 1274.2234 and a EV to EBITDA ratio of -2.1258. Its price to sales ratio in the trailing 12-months stood at 1174.391.
Cytodyn Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $14.64 million
- Total Liabilities
- $121.33 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Cytodyn Inc ended 2025 with $14.64 million in total assets and $0 in total liabilities. Its intangible assets were valued at $14.64 million while shareholder equity stood at $-107010000.00.
Cytodyn Inc ended 2025 with $0 in deferred long-term liabilities, $121.33 million in other current liabilities, 837000.00 in common stock, $-823054000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $11.11 million and cash and short-term investments were $11.11 million. The company’s total short-term debt was $36,013,000 while long-term debt stood at $0.
Cytodyn Inc’s total current assets stands at $14.11 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $81.96 million and inventory worth $0.
In 2025, Cytodyn Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Cytodyn Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $0.2
- 52-Week High
- $1.26
- 52-Week Low
- $0.15
- Analyst Target Price
- $
Cytodyn Inc stock is currently trading at $0.2 per share. It touched a 52-week high of $1.26 and a 52-week low of $1.26. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.23 and 200-day moving average was $0.28 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 600.6% of the company’s stock are held by insiders while 5.5% are held by institutions.
Frequently Asked Questions About Cytodyn Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (“COVID-19”). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.